CHEK2 and breast cancer: An alternative approach (strategy #2) could entail discontinuing the ascertainment of family history of breast cancer and instead refer all women with a pathogenic variant in BRCA1, BRCA2, PALB2, ATM, and CHEK2 or a PRS in the top 10% (Supplemental Figure 5B, Supplemental Table 11).